Literature DB >> 21512807

MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy.

M Roethke1, A G Anastasiadis, M Lichy, M Werner, P Wagner, S Kruck, Claus D Claussen, A Stenzl, H P Schlemmer, D Schilling.   

Abstract

PURPOSE: To investigate the positive biopsy rate of MRI-guided biopsy (MR-GB) in a routine clinical setting, identify factors predictive for positive biopsy findings and to report about the clinical significance of the diagnosed tumors.
METHODS: Patients with at least one negative trans-rectal-ultrasound-guided biopsy (TRUS-GB), persistently elevated or rising serum prostate specific antigen (PSA) and at least one lesion suspicious for PCa on diagnostic 1.5 Tesla endorectal coil MRI (eMR) were included. Biopsies were carried out using a 1.5 Tesla MRI and an 18 G biopsy gun. Clinical information and biopsy results were collected; logistic regression analysis was carried out. Definite pathology reports of patients with diagnosis of PCa and subsequent radical prostatectomy (RP) were analyzed for criteria of clinical significance.
RESULTS: One hundred patients were included, mean number of previous biopsies was 2 (range 1-9), mean PSA at time of biopsy was 11.7 ng/ml (1.0-65.0), and mean prostate volume was 46.7 ccm (range 13-183). In 52/100 (52.0%) patients, PCa was detected. Out of 52 patients, 27 patients with a positive biopsy underwent RP, 20 patients radiation therapy, and 5 patients active surveillance. In total, 80.8% of the patients revealed a clinically significant PCa. In univariate regression analysis, only serum PSA levels were predictive for a positive biopsy result. Number of preceding negative biopsies was not associated with the likelihood of a positive biopsy result.
CONCLUSIONS: MR-GB shows a high detection rate of clinically significant PCa in patients with previous negative TRUS-GB and persisting suspicion for PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512807     DOI: 10.1007/s00345-011-0675-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

1.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.

Authors:  Aristotelis G Anastasiadis; Matthias P Lichy; Udo Nagele; Markus A Kuczyk; Axel S Merseburger; Joerg Hennenlotter; Stefan Corvin; Karl-Dietrich Sievert; Claus D Claussen; Arnulf Stenzl; Heinz-Peter Schlemmer
Journal:  Eur Urol       Date:  2006-03-24       Impact factor: 20.096

2.  Origin and development of carcinoma in the prostate.

Authors:  J E McNeal
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

Review 3.  Prostate biopsy: who, how and when. An update.

Authors:  Bob Djavan; Shirin Milani; Mesut Remzi
Journal:  Can J Urol       Date:  2005-02       Impact factor: 1.344

4.  Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.

Authors:  Alessandro Sciarra; Valeria Panebianco; Mauro Ciccariello; Stefano Salciccia; Susanna Cattarino; Danilo Lisi; Alessandro Gentilucci; Andrea Alfarone; Silvia Bernardo; Roberto Passariello; Vincenzo Gentile
Journal:  Clin Cancer Res       Date:  2010-03-02       Impact factor: 12.531

5.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device.

Authors:  K Engelhard; H P Hollenbach; B Kiefer; A Winkel; K Goeb; D Engehausen
Journal:  Eur Radiol       Date:  2006-02-01       Impact factor: 5.315

6.  The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer.

Authors:  M Norberg; L Egevad; L Holmberg; P Sparén; B J Norlén; C Busch
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

7.  Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology.

Authors:  Apostolos P Labanaris; Vahudin Zugor; Robert Smiszek; Reinhold Nützel; Reinhard Kühn; Karl Engelhard
Journal:  Magn Reson Imaging       Date:  2010-04-24       Impact factor: 2.546

8.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.

Authors:  Thomas Hambrock; Diederik M Somford; Caroline Hoeks; Stefan A W Bouwense; Henkjan Huisman; Derya Yakar; Inge M van Oort; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

9.  MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results.

Authors:  Stephan Zangos; Katrin Eichler; Kerstin Engelmann; Mukhtiar Ahmed; Sebastian Dettmer; Christopher Herzog; Wasilios Pegios; A Wetter; Thomas Lehnert; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2004-09-04       Impact factor: 5.315

10.  Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy.

Authors:  Byung Kwan Park; Hyun Moo Lee; Chan Kyo Kim; Han Yong Choi; Jong Wook Park
Journal:  Invest Radiol       Date:  2008-11       Impact factor: 6.016

View more
  64 in total

Review 1.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.

Authors:  Iqbal Sahibzada; Deepak Batura; Giles Hellawell
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

Review 3.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

4.  Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Authors:  D M Somford; W Vreuls; T S Jansen; J P van Basten; H Vergunst
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

5.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

6.  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.

Authors:  M C Roethke; T H Kuru; S Schultze; D Tichy; A Kopp-Schneider; M Fenchel; H-P Schlemmer; B A Hadaschik
Journal:  Eur Radiol       Date:  2013-10-03       Impact factor: 5.315

Review 7.  Recent advances in imaging-guided interventions for prostate cancers.

Authors:  Xia Wu; Feng Zhang; Ran Chen; Weiliang Zheng; Xiaoming Yang
Journal:  Cancer Lett       Date:  2014-04-24       Impact factor: 8.679

8.  3T MR-guided in-bore transperineal prostate biopsy: A comparison of robotic and manual needle-guidance templates.

Authors:  Gaurie Tilak; Kemal Tuncali; Sang-Eun Song; Junichi Tokuda; Olutayo Olubiyi; Fiona Fennessy; Andriy Fedorov; Tobias Penzkofer; Clare Tempany; Nobuhiko Hata
Journal:  J Magn Reson Imaging       Date:  2014-09-27       Impact factor: 4.813

9.  Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer.

Authors:  Soroush Rais-Bahrami; Baris Turkbey; Kinzya B Grant; Peter A Pinto; Peter L Choyke
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

10.  Pathologic findings in patients with targeted magnetic resonance imaging-guided prostate needle core biopsies.

Authors:  Rachel L Geller; Sherif G Nour; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.